On Wednesday, October 11, 2023, we teamed up with Cyberport, HKMHDIA, and UMP Innov Centre to host the “Bright Ideas, Strong Barriers: A Patenting Masterclass” seminar, both in-person and online. Jennifer, our Managing Director, and Pauli, our Principal, took the stage and delivered presentations on the fundamentals of intellectual property (IP) and the challenges faced in MedTech/Healthcare innovation within the GBA and China.

We were privileged to have a distinguished panel of experts who generously shared their experiences and insights on the topic of “MedTech Innovations and Intellectual Property Protection.” Our esteemed panelists included Ronnie Li from UMP Healthcare Group as the moderator, Dr. Lydia Leung from HKMHDIA and Belun Technology, Mr. Justin Chan from Gense Technologies, Ms. Kim Chow from LinkAIQ, and our very own Managing Director, Ms. Jennifer Che.

At Eagle IP Limited, our mission is to assist both local and foreign inventors in safeguarding their creations and business endeavors. Through seminars like these, we aim to raise awareness about the importance of IP in the technology industry. We eagerly anticipate organizing more IP workshops and events for our community!






Our Past Events

Recommended Insights

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

19 October 2021
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]

What is the difference between an Invention Patent and a Utility Model Patent?

13 August 2021
There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

1 April 2025
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right